First, a message from our friends at Med-X (sponsor)

Why Are Investors Looking at Med-X Before Its Planned Nasdaq Listing?

Here's the simple idea: the biggest upside often happens before a company goes public.

Med-X is preparing for a potential Nasdaq listing (ticker: MXRX) - and right now, investors have a chance to get in before public market pricing kicks in.

When companies are still private, shares are typically offered at a fixed valuation based on fundamentals. Once they hit the public markets? That's when broader demand, momentum, and future expectations can drive prices higher.

That early gap is where some investors look for opportunity.

What's Already in Place

  • Nasdaq ticker MXRX reserved
  • Listing qualifications nearing completion
  • Backed by Maxim Group Investment Bank
  • Zero long-term debt
  • Established and growing revenue

Get In Before the Bell Rings

Shares are currently available at $4 each - before any potential Nasdaq debut.

So, What Is Med-X?

Med-X is focused on replacing traditional chemical pesticides with plant-based, safer alternatives.

  • Millions in sales
  • Operating across 41 markets
  • Positioned to capture the surging global demand for sustainable, safer pest control solutions

As industries shift toward cleaner, safer products, companies in this space are starting to get more attention.

The Bigger Picture

We've seen how emerging sectors start quietly - then gain momentum as the market begins to recognize their potential, from SaaS to telehealth and beyond.

A similar shift is underway in pest control, where global demand is moving toward safer, more sustainable solutions.

As that transition continues, some investors are watching whether clean pest control could follow a familiar pattern: early-stage adoption, followed by broader market recognition - this time in a category that's only just beginning to evolve.

Bottom Line

If you're interested in getting in before a potential Nasdaq listing, this is the window many investors pay attention to.

Explore Med-X and learn how to become a shareholder at $4/share


Disclosures
This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com


Wall Street’s Pre-IPO Playbook

There's a version of IPO investing most people never see.

By the time a company rings the opening bell on the Nasdaq, the biggest money has already been made. The venture capitalists, the hedge funds, the mutual funds — they bought shares at a big discount several months or years ago.

This isn't a secret, exactly. But most investors don't know how it actually works — or when it started.

The shift happened gradually over the past 30 years. Before the mid-1990s, late-stage startup funding was almost exclusively the domain of dedicated venture capital firms.

A 1996 law called the National Securities Markets Improvement Act quietly changed the rules. It made it far easier for large mutual funds and hedge funds to invest in private companies.

The IPO market has never been the same.

Fidelity moved fast. By the early 2000s, the firm was writing checks in private rounds for companies most retail investors had never heard of.

Before Facebook's 2012 IPO, T. Rowe Price invested roughly $190 million at around $25 per share. Fidelity followed in the secondary market at similar prices. Facebook went public at a $104 billion valuation. Both firms held massive positions on day one — already sitting on enormous gains.

The same playbook repeated with Uber, Airbnb, Dropbox, Pinterest, and Spotify. Fidelity's Contrafund alone held stakes in roughly 50 private tech companies by the mid-2010s.

Hedge funds got aggressive too. Tiger Global completed over 272 late-stage private deals since 2015. Coatue brought the same momentum-driven approach it used in public markets into private rounds. These funds were fast, wrote big checks, and asked fewer questions than traditional VCs.

The numbers tell the story.

In 2016, late-stage private capital — the money flowing into companies before they go public — totaled roughly $15.7 billion. By 2025, that figure had grown to more than $114 billion annually. That's not a blip.

That's Wall Street systematically reallocating capital away from public markets and into private ones, at a scale that would have been unimaginable a generation ago.

The scale of this is striking. In peak years, non-traditional investors — mutual funds, hedge funds, sovereign wealth funds — accounted for 73 to 80 percent of late-stage deal value. By 2020, nearly three-quarters of all IPOs had raised crossover capital before going public.

There's a reason these firms do this. Mature public tech companies grow more slowly. Private companies at the right stage can grow 5x, 10x, or more before they even file an S-1.

For a long time, individual investors couldn't participate. Minimums were $1 million or more. You needed to be an institutional fund or a qualified purchaser with $25 million in investable assets.

That's been changing. Regulation A and Regulation CF, both expanded under the JOBS Act, now allow private companies to raise capital from everyday investors with minimums as low as a few hundred dollars.

Ian Wyatt
Editor, IPO Watch

This issue is sponsored content. The sponsor is conducting a Reg A securities offering. This is not a recommendation to buy or sell any security. Investing in early-stage companies involves significant risk, including possible loss of principal.

Recommended for you

View all
caret-right